Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Ord Shs RLFTF

Healthcare Biotechnology
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of... see more

Recent & Breaking News (OTCQB:RLFTF)

Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting

ACCESS Newswire July 22, 2021

Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

ACCESS Newswire July 20, 2021

Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial

ACCESS Newswire July 13, 2021

NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI(TM) (Aviptadil-acetate) Trial in the Nation of Georgia

PR Newswire July 6, 2021

Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

ACCESS Newswire June 29, 2021

Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority

ACCESS Newswire June 21, 2021

Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

ACCESS Newswire June 16, 2021

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration

ACCESS Newswire June 2, 2021

NRx Pharmaceuticals Announces Positive Results for ZYESAMI(TM) (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure

PR Newswire June 1, 2021

Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer

ACCESS Newswire May 28, 2021

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG

ACCESS Newswire May 27, 2021

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

GlobeNewswire May 25, 2021

Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders

ACCESS Newswire May 18, 2021

Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray

ACCESS Newswire May 17, 2021

Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

ACCESS Newswire May 4, 2021

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome

ACCESS Newswire April 22, 2021

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

ACCESS Newswire April 19, 2021

Relief Reports 2020 Financial Results and Provides Business Update

ACCESS Newswire April 15, 2021

Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant

ACCESS Newswire April 7, 2021

NeuroRx Announces Zyesami(TM) (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

PR Newswire April 6, 2021